Key Points A pooled analysis of 111 patients with metastatic breast cancer found that an immune marker measured after treatment was associated with clinical outcomes….
October 22, 2026
Korro Reports Encouraging RNA-Editing Results for KRRO-111, Targets Regulatory Submission in 2027
Key Points Korro Bio’s experimental KRRO-111 showed strong RNA-editing activity in laboratory and mouse studies for alpha-1 antitrypsin deficiency, or AATD. Repeat-dose mouse studies achieved…
October 21, 2026
Psyence BioMed Completes $2.6 Million PsyLabs Investment as Ibogaine Program Advances
Key Points Psyence BioMed invested an additional $2.6 million in PsyLabs after two development milestones were met. PsyLabs completed a regulatory preparation package, while Psyence’s…
October 21, 2026
Opus Genetics Gets FDA Clearance to Begin Gene Therapy Trial for Inherited Childhood Blindness
Key Points The FDA cleared Opus Genetics’ application to begin clinical testing of OPGx-RDH12 for a rare inherited retinal disease. Opus plans to initiate a…
October 20, 2026
Palisade Bio Reports Early Crohn’s Disease Improvements as PALI-2108 Advances in Phase 2
Key Points Five Crohn’s disease patients showed a 47.5% reduction in average endoscopic disease activity after 14 days of PALI-2108 treatment. Average fecal calprotectin, a…
Key Points The FDA has cleared Anavex to proceed with a U.S. clinical study of blarcamesine in Fragile X syndrome. The planned Phase 2a trial…
October 12, 2026
vTv Therapeutics Highlights Opportunity to Improve Type 1 Diabetes Care Alongside Automated Insulin Delivery
Key Points A survey presented by vTv Therapeutics found that low blood sugar remains a concern for many adults with type 1 diabetes who use…
October 08, 2026
Perspective Therapeutics Wins FDA Fast Track Status for Targeted Therapy in Rare Tumors
Key Points The FDA granted Fast Track designation to PSV359 for adults with FAP-positive solitary fibrous tumors that are locally advanced and unresectable and/or metastatic….
Key Points Enliven Therapeutics reached FDA alignment on the final design of ENABLE-2, its pivotal Phase 3 trial of relcobatinib in previously treated chronic myeloid…
Key Points Korro Bio dosed the first healthy-volunteer cohort in ANCHOR, its Phase 1/2 trial of KRRO-121. Participants in the first cohort received a single…
October 05, 2026
vTv Fully Enrolls Phase 3 Cadisegliatin Trial in Type 1 Diabetes
Key Points vTv Therapeutics has completed enrollment in its Phase 3 CATT1 study of cadisegliatin as an add-on treatment to insulin for adults with type…
October 02, 2026
Surrozen Clears FDA IND Hurdle for DME Drug, Unlocking $95.1 Million Financing Milestone
Key Points The FDA has cleared Surrozen’s investigational new drug application for SZN-8141, enabling clinical development in diabetic macular edema. Surrozen expects to dose the…